Combined use of oral chelators and desferrioxamine in thalassemia

Piga, Antonio; Roggero, Simona; Marletto, Fabio; Sacchetti, L; Longo, Filomena

doi:10.1080/10245330512331389737

Cited by 4 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination treatment (two drugs daily taken at full doses and simultaneously or alternating the two drugs during the week) may be considered every time there is a need to look for an additive or synergistic effect in patients with severe iron overload and heart disease 22,23. A single uncontrolled study suggests that combination therapy (DFO plus DFP) may reverse endocrine complications such as glucose intolerance in patients with TM 24.…”

Section: Management Of β-Thalassemia Majormentioning

confidence: 99%

The Icet-a Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients

Sanctis¹

2016

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Iron overload in patients with thalassemia major (TM) affects glucose regulation and is mediated by several mechanisms. The pathogenesis of glycaemic abnormalities in TM is complex and multifactorial. It has been predominantly attributed to a combination of reduced insulin secretory capacity and insulin resistance. The exact mechanisms responsible for progression from norm glycaemia to overt diabetes in these patients are still poorly understood but are attributed mainly to insulin deficiency resulting from the toxic effects of iron deposited in the pancreas and insulin resistance. A group of endocrinologists, haematologists and paediatricians, members of the International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine (ICET-A) convened to formulate recommendations for the diagnosis and management of abnormalities of glucose homeostasis in thalassemia major patients on the basis of available evidence from clinical and laboratory data and consensus practice. The results of their work and discussions are described in this article.

show abstract

Section: Management Of β-Thalassemia Majormentioning

confidence: 99%

The Icet-a Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients

Sanctis¹

2016

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…Effectiveness of this modality of treatments depends primarily on compliance of the medication. [7] Deferiprone (Ferriprox) is another oral chelator, which was recently approved in many countries including the United States. [8] The most common post-therapeutic complication due to iron chelation is liver brosis.…”

Section: Introductionmentioning

confidence: 99%

Endocrine Complications and the Effect of Compliance to Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia

Habbash¹,

AlBati²,

Alhashim³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Endocrinopathies and metabolic complications are common in Beta Thalassemia major patients receiving blood transfusion. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties to adhere with chelation therapy due to several reasons.Aim: To evaluate endocrine complications in beta thalassemia major patients (2-30 years) in The Eastern Province of Saudi Arabia and compare the onset of endocrine complications among compliant and non-compliant patients. Moreover, assess the barriers that hinder the compliance on chelating therapy.Methods: A Cross-sectional study was conducted on 89 patients (43 male and 46 females) in patients aged 2 to 30 years attending different hospitals in the Eastern province of Saudi Arabia. A semi-structured questionnaire was used to collect demographic data, medical histories. The questionnaires were filled by face-to-face interviews with the patients, or their care givers and the required laboratory data was retrieved from the medical records of patients.Results: The most prevalent abnormality was underweight detected in (40.9 %) of patients followed by subclinical hypothyroidism (37.7 %), short stature (35.2 %), hypothyroidism in (17.0 %) and diabetes mellitus in (13.6 %). Significant difference between those who are compliant to iron chelation therapy and those who are not in terms of the prevalence of short stature (P value= .05) and hypothyroidism (P value= .05) being the most evident. Percentage of Patients who were not compliant on taking chelation therapy is (21.6 %) and (9.1 %) of patients were not taking them at all. Conclusion: Despite the role of chelation therapy in the management of iron overload, the risk of secondary endocrine and metabolic complications remained considerable. Subclinical hypothyroidism and short stature were the most frequent endocrine complications encountered in this study.

show abstract

“…The effectiveness of this modality of treatment depends primarily on compliance with the medication. 7 Deferiprone (Ferriprox) is another oral chelator that was recently approved in many countries, including the United States. 8 The most common post-therapeutic complication due to iron chelation is liver fibrosis.…”

Section: Introductionmentioning

confidence: 99%

Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia

Habbash¹,

Al-Bati²,

Al-Hashim³

et al. 2022

JBM

View full text Add to dashboard Cite

Background Endocrinopathies and metabolic complications are common in beta thalassemia major patients receiving blood transfusions. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties adhering to chelation therapy for several reasons. Aim To evaluate endocrine complications in beta thalassemia major patients (2–30 years) in the Eastern Province of Saudi Arabia and compare the onset of endocrine complications among compliant and noncompliant patients. Moreover, we assessed the barriers that hinder compliance with chelating therapy. Methods A cross-sectional study was conducted on 89 patients (43 males and 46 females) aged 2 to 30 years attending different hospitals in the Eastern Province of Saudi Arabia. A semi-structured questionnaire was used to collect demographic data and medical histories. The questionnaires were completed by face-to-face interviews with the patients or their caregivers, and the required laboratory data were retrieved from the medical records of patients. Results The most prevalent abnormality was underweight detected in (40.9%) of patients, followed by subclinical hypothyroidism (37.7%), short stature (35.2%), hypothyroidism in (17.0%) and diabetes mellitus in (13.6%). A significant difference between those who were compliant with iron chelation therapy and those who were not in terms of the prevalence of short stature ( P value= 0.05 ) and hypothyroidism ( P value= 0.05 ). The percentage of patients who were not compliant with chelation therapy was 21.6% and 9.1% of patients were not taking them at all. Conclusion Despite the role of chelation therapy in the management of iron overload, the risk of secondary endocrine and metabolic complications remained considerable. Subclinical hypothyroidism and short stature were the most frequent endocrine complications encountered in this study.

show abstract

Combined use of oral chelators and desferrioxamine in thalassemia

Cited by 4 publications

References 14 publications

The Icet-a Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients

The Icet-a Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients

Endocrine Complications and the Effect of Compliance to Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia

Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia

Contact Info

Product

Resources

About